Recurrent
clostridioides difficile
emerging infections program
fecal microbiota transplantation
real-world therapy utilization
recurrent clostridioides difficile
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
received:
12
03
2024
accepted:
12
06
2024
medline:
8
7
2024
pubmed:
8
7
2024
entrez:
8
7
2024
Statut:
epublish
Résumé
Fecal microbiota transplantation (FMT) is recommended for the treatment of recurrent A retrospective community-wide cohort study was conducted using surveillance data from the Georgia Emerging Infections Program, the Georgia Discharge Data System, and locally maintained lists of FMTs completed across multiple institutions to evaluate all episodes of A total of 3038 (22%) of 13 852 patients with CDI had rCDI during this period. In a propensity-matched cohort, patients who received an FMT had lower rates of rCDI (odds ratio, 0.6 [95% confidence interval, .38-.96) and a lower mortality rate (0.26 [.08-.82]). Of patients with rCDI, only 6% had received FMT. Recipients were more likely to be young, white, and female and less likely to have renal disease, diabetes, or liver disease, though these chronic illnesses were associated with higher rates of rCDI. These data suggest FMT has been underused in a population-based assessment and that FMT substantially reduced risk of recurrence and death.
Sections du résumé
Background
UNASSIGNED
Fecal microbiota transplantation (FMT) is recommended for the treatment of recurrent
Methods
UNASSIGNED
A retrospective community-wide cohort study was conducted using surveillance data from the Georgia Emerging Infections Program, the Georgia Discharge Data System, and locally maintained lists of FMTs completed across multiple institutions to evaluate all episodes of
Results
UNASSIGNED
A total of 3038 (22%) of 13 852 patients with CDI had rCDI during this period. In a propensity-matched cohort, patients who received an FMT had lower rates of rCDI (odds ratio, 0.6 [95% confidence interval, .38-.96) and a lower mortality rate (0.26 [.08-.82]). Of patients with rCDI, only 6% had received FMT. Recipients were more likely to be young, white, and female and less likely to have renal disease, diabetes, or liver disease, though these chronic illnesses were associated with higher rates of rCDI.
Conclusions
UNASSIGNED
These data suggest FMT has been underused in a population-based assessment and that FMT substantially reduced risk of recurrence and death.
Identifiants
pubmed: 38975247
doi: 10.1093/ofid/ofae309
pii: ofae309
pmc: PMC11227225
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofae309Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. C. S. K has served as a scientific advisor to Seres Therapeutics and a consultant to Ferring/Rebiotix. S. K. F. reports that Emory University has received a service agreement from Pfizer for public health research on Clostridioides difficile, starting in 2019 for 2 years. All other authors report no potential conflicts.